Eyebright Medtech Plans Private Placement to Expand Contact Lens Production
China-based Eyebright Medical Technology (Beijing) Co., Ltd. (SHA: 688050), an ophthalmic medical device manufacturer, announced...
Sinocelltech’s Finotonlimab Gets NMPA Approval for Liver Cancer Treatment
China-based Sinocelltech Group Ltd (SHA: 688520) announced that it has received another indication approval from...
Danatlas Raises RMB 150M to Advance Synthetic Lethality Drug Pipeline
Beijing-headquartered Danatlas, a first-in-class drug developer in the synthetic lethality field, has reportedly raised RMB...
Magnet Biomedicine and Eli Lilly Partner on Molecular Glue Therapeutics
US-based molecular glue specialist Magnet Biomedicine has entered into a collaboration and license agreement with...
AstraZeneca and Amgen’s Tezspire Shows Positive Results in Phase III Study
AstraZeneca (NASDAQ: AZN) and Amgen (NASDAQ: AMGN) have jointly announced positive results from the Phase...
Baidu Health Partners with Jolly Pharma to Boost Digital Drug Marketing
Baidu Health, an internet giant, has entered into a partnership with Zhejiang Jolly Pharmaceutical Co.,...
Duality Biotherapeutics Updates IPO Filing with HKSE under Chapter 18A Rules
China-based Duality Biotherapeutics, Inc. updated its initial public offering (IPO) filing to the Hong Kong...
CARsgen’s CT041 Awarded Breakthrough Therapy Designation for Gastric Cancer
CARsgen Therapeutics Holdings Ltd (HKG: 2171) announced that its chimeric antigen receptor (CAR) T-cell therapy,...
Huge Dental Files for Hong Kong IPO with Diverse Dental Product Portfolio
Shandong-based dental materials company Huge Dental Limited has made an initial public offering (IPO) filing...
CSPC Pharmaceutical’s Sirolimus Receives BTD for Malignant PEComa Treatment
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that it has received Breakthrough Therapy Designation...
Pulnovo Medical Raises USD 100M in Series C Financing for Global Expansion
Wuxi-based Pulnovo Medical Limited, a developer of medical devices for pulmonary hypertension and heart failure,...
Grand Pharma Sells Telix Shares for AUD 143M to Fund Clinical Programs
China-based Grand Pharmaceutical Group Co., Ltd. (HKG: 0512) announced the sale of 4,947,181 shares in...
AI in Healthcare: Accelerating Applications in Diagnostics and Multi-omics Analysis
The breakthrough technology of DeepSeek has significantly accelerated the application of AI in the medical...
Biointron Biologics Files for Public Offering, Aims for BSE Listing
On February 11, Biointron Biologics released its tutoring filing report for the public offering of...
Biocytogen Completes DeepSeek Localization, Integrates with “Thousand Mice, Ten Thousand Antibodies” Plan
On February 28, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (HKG: 2315) announced that it has completed...
BeiGene’s Q4 and 2024 Financials Highlight Significant Growth and Product Success
BeiGene, Ltd. (NASDAQ: ONC, HKG: 6160, SHA: 688235) released financial results and corporate updates from...
Zai Lab Q2 and Full-Year 2024 Report Shows Sales Growth and Loss Reduction
China-based biotech Zai Lab Ltd (NASDAQ: ZLAB, HKG: 9688) released its Q2 and full-year 2024...
Viatris Q4 and Full-Year Results Show Greater China Growth
US generics giant Viatris (NASDAQ: VTRS) released its Q4 and full-year 2024 financial results. In...
SciClone Pharmaceuticals Licenses Eisai’s Tasurgratinib for China
China-based SciClone Pharmaceuticals Inc. announced a licensing agreement with Eisai Co., Ltd (TYO: 4523), securing...
Fosun Pharmaceutical’s XS-03 Gets NMPA Green Light for CRC Study
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that it has...